|Title:||2014 guidelines of taiwan society of cardiology (TSOC) for the management of pulmonary arterial hypertension||Authors:||Hsu C.-H.
|Issue Date:||2014||Publisher:||Republic of China Society of Cardiology||Journal Volume:||30||Journal Issue:||5||Start page/Pages:||401-444||Source:||Acta Cardiologica Sinica||Abstract:||
Pulmonary hypertension (PH) is a hemodynamic and pathophysiologic condition, defined as a mean pulmonary arterial pressure exceeding 25 mmHg at rest. According to the recent classifications, it is grouped into pulmonary arterial hypertension (PAH), heart-related, lung-related, thromboembolic, and miscellaneous PH. In the past two decades, tremendous advances have occurred in the field of PH. These include (1) development of clinical diagnostic algorithm and a monitoring strategy dedicated to PAH, (2) defining strong rationales for screening at-risk populations, (3) advent of pulmonary specific drugs which makes PAH manageable, (4) recognition of needs of having proper strategy of combining existing pulmonary specific drugs, and/or potential novel drugs, (5) pursuit of clinical trials with optimal surrogate endpoints and study durations, (6) recognition of critical roles of PH/right ventricular function, as well as interdependence of ventricles in different conditions, especially those with various phenotypes of heart failure, and (7) for rare diseases, putting equal importance on carefully designed observation studies, various registries, etc., besides double blind randomized studies. In addition, ongoing basic and clinical research has led to further understanding of relevant physiology, pathophysiology, epidemiology and genetics of PH/PAH. This guidelines from the working group of Pulmonary Hypertension of the Taiwan Society of Cardiology is to provide updated guidelines based on the most recent international guidelines as well as Taiwan's domestic research on PH. The guidelines aremainly for themanagement of PAH (Group 1); however themajority of content can be helpful for managing other types of PH.
|ISSN:||1011-6842||metadata.dc.subject.other:||ambrisentan; amino terminal pro brain natriuretic peptide; anticoagulant agent; beraprost; bosentan; brain natriuretic peptide; calcium channel blocking agent; digoxin; diuretic agent; endothelin receptor antagonist; iloprost; macitentan; oxygen; phosphodiesterase V inhibitor; prostacyclin; prostanoid; riociguat; sildenafil; tadalafil; toxin; treprostinil; troponin T; uric acid; arterial gas; balloon dilatation; birth control; cardiopulmonary exercise test; cardiovascular risk; chronic thromboembolic pulmonary hypertension; clinical classification; clinical feature; computed tomographic angiography; computer assisted tomography; congenital heart disease; connective tissue disease; disease association; disease severity; echocardiography; echography; exercise; exercise test; genetic disorder; heart arrhythmia; heart catheterization; heart disease; heart failure; heart right ventricle function; heart transplantation; hematologic disease; hemodynamic parameters; histology; human; hypoxemia; hypoxia; idiopathic disease; long term survival; lung angiography; lung artery pressure; lung disease; lung function test; lung scintiscanning; lung transplantation; medical society; metabolic disorder; nuclear magnetic resonance imaging; patient education; physical activity; portal hypertension; practice guideline; pregnancy; prognosis; pulmonary capillary hemangiomatosis; pulmonary hypertension; pulmonary veno-occlusive disease; rare disease; Review; systemic disease; systemic lupus erythematosus; systemic pulmonary shunt; Taiwan; thorax radiography; vaccination; venous thromboembolism
|Appears in Collections:||醫學系|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.